PMID- 14723834
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200930
IS  - 1092-8472 (Print)
IS  - 1092-8472 (Linking)
VI  - 7
IP  - 1
DP  - 2004 Feb
TI  - Gastrointestinal Stromal Tumors Respond to Tyrosine Kinase-targeted Therapy.
PG  - 13-17
AB  - Gastrointestinal stromal tumors (GISTs) are rare tumors of the wall of the 
      stomach and small bowel, and also occasionally arise in the mesentery, omentum, 
      or retroperitoneum. The incidence of GIST in the United States is approximately 
      500 to 750 patients per 100,000 people. GISTs often present late in their 
      clinical course unless they are the cause of gastrointestinal bleeding or 
      perforation. Surgical resection is the standard of care for primary GIST. 
      However, there is a high risk of recurrence in the peritoneum and liver. For 
      metastatic GIST, imatinib mesylate is the standard of care. Two phase III studies 
      presented in 2003 in abstract form show slightly different results. In the US 
      study, 400 mg/d was found to be equivalent to 800 mg/d with respect to response, 
      progression-free survival, and overall survival at 12 months. In the 
      European/Australasian study, the response rate was the same with either dosage, 
      but progression-free survival was better with 800 mg/d compared with 400 mg/d. 
      Overall survival data for the latter study were too immature for analysis as of 
      May 2003. Adjuvant or neoadjuvant therapy with imatinib is the topic of at least 
      three studies through the American College of Surgeons Oncology Group and 
      Radiation Therapy Oncology Group and the American College of Radiology Imaging 
      Network. Every effort to enroll eligible patients on these studies should be 
      made. New treatments for metastatic disease under investigation include a 
      tyrosine kinase inhibitor with an expanded panel of targets compared with 
      imatinib (SU011248), and the addition of a mammalian target of rapamycin (mTOR) 
      inhibitor and the rapamycin derivative RAD001 to imatinib. Given the finding of a 
      specific molecular defect to exploit, GISTs have gone from an orphan disease to a 
      proving ground for tyrosine kinase-targeted therapy.
FAU - Maki, Robert G
AU  - Maki RG
AD  - Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, 
      New York, NY 10021, USA. makir@mskcc.org
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Curr Treat Options Gastroenterol
JT  - Current treatment options in gastroenterology
JID - 9815941
EDAT- 2004/01/16 05:00
MHDA- 2004/01/16 05:01
CRDT- 2004/01/16 05:00
PHST- 2004/01/16 05:00 [pubmed]
PHST- 2004/01/16 05:01 [medline]
PHST- 2004/01/16 05:00 [entrez]
AID - 10.1007/s11938-004-0021-5 [doi]
PST - ppublish
SO  - Curr Treat Options Gastroenterol. 2004 Feb;7(1):13-17. doi: 
      10.1007/s11938-004-0021-5.